Pharmaceutical Sales: 70%
OTC Products: 20%
Veterinary Products: 10%

TOP 3 Markets:
India: 45%
USA: 25%
Russia: 15%

J. B. Chemicals & Pharmaceuticals Limited generates the majority of its sales from the pharmaceutical industry, with prescription drugs accounting for the largest share. The Indian market is the most significant, followed by the USA and Russia. These markets are crucial for the company as they provide a stable demand for pharmaceutical and OTC products. Diversification into different regions helps the company minimize market risks and capitalize on growth opportunities.

Production Sites:

1. India - Main production facilities
2. Daman - Specialized production plant
3. Ankleshwar - Production site for pharmaceutical active ingredients

J. B. Chemicals & Pharmaceuticals Limited produces the majority of its products in India. The main production facilities are located in Daman and Ankleshwar. These sites specialize in the production of pharmaceutical active ingredients and finished pharmaceutical products. The company has focused on adhering to international quality standards to serve both the domestic and international markets.

Revenue Growth: 18% (estimated for 2026)
Research and Development Investments: 10% of revenue (2026)

J. B. Chemicals & Pharmaceuticals Limited pursues a growth strategy that heavily relies on innovation and expansion into new markets. The company invests significantly in research and development to expand its product pipeline and introduce new, innovative drugs to the market. These investments account for approximately 10% of revenue and are intended to strengthen the company's competitiveness.

In addition, the company focuses on geographical expansion, particularly in emerging markets, to benefit from the increasing demand for pharmaceutical products. Partnerships and strategic alliances with local players are utilized to facilitate market entry and enhance market presence.

Another focus is on optimizing production processes and implementing modern technologies to increase efficiency and reduce costs. These measures are aimed at improving margins and positioning the company strongly for future growth.

Imported Raw Materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials

Countries of Origin: China, Germany, USA, India (local procurement)

J. B. Chemicals & Pharmaceuticals Limited primarily imports active pharmaceutical ingredients (APIs) and excipients that are essential for the production of their products. A significant portion of these raw materials is sourced from China, as the country is one of the largest producers of APIs worldwide. In addition, special chemicals and high-quality excipients are imported from Germany and the USA to ensure quality standards.

In addition to international procurement sources, the company also utilizes local suppliers in India to source packaging materials and certain excipients, diversifying the supply chain and reducing potential risks associated with international dependencies.

Market share in India: 3.5% (2025) R&D expenses: 8% of revenue (2025) EBITDA margin: 25% (2025)

J. B. Chemicals & Pharmaceuticals Limited has a significant competitive advantage that manifests in several areas. The company holds a solid market share of 3.5% in the Indian pharmaceutical market, indicating a strong brand presence and a wide product portfolio.

The investments in research and development, amounting to 8% of revenue, demonstrate the company's commitment to innovation and the development of new products. This strengthens its competitive position by allowing the company to differentiate itself from competing products and quickly respond to changing market needs.

With an EBITDA margin of 25%, the company shows strong operational efficiency and cost control. This high margin enables J. B. Chemicals to remain profitable in a competitive market while also investing in growth and expansion.

In summary, J. B. Chemicals & Pharmaceuticals Limited has a clear competitive advantage in the pharmaceutical sector through its market position, innovation capabilities, and operational efficiency.

Institutional Investor Share: Estimated at around 30-35% (2026)

Insider Buys/Sells: No significant transactions in the last year (2026)

The institutional investor share in J. B. Chemicals & Pharmaceuticals Limited is estimated to be between 30 and 35 percent. This demonstrates institutional investors' confidence in the company's long-term performance.

Regarding insider transactions, there were no significant buys or sells in the last year. This could indicate that the management has confidence in the current company strategy and does not expect any short-term changes.

Market share of J. B. Chemicals & Pharmaceuticals Limited: 3.5% (estimated, 2026)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 8.2%
2. Dr. Reddy's Laboratories: 7.5%
3. Cipla Limited: 6.9%
4. Lupin Limited: 6.3%
5. Aurobindo Pharma: 5.8%
6. Torrent Pharmaceuticals: 4.7%
7. Zydus Lifesciences: 4.2%
8. J. B. Chemicals & Pharmaceuticals Limited: 3.5%
9. Biocon Limited: 3.3%
10. Glenmark Pharmaceuticals: 3.0%

Moat of J. B. Chemicals & Pharmaceuticals Limited:

J. B. Chemicals & Pharmaceuticals Limited has made a name for itself in certain niche markets, such as the production of cardiovascular drugs and antacids. The company's moat is based on its strong brand recognition in these segments and a well-established distribution network in India and selected international markets.

Compared to larger competitors like Sun Pharmaceutical and Dr. Reddy's Laboratories, which have more extensive product portfolios and larger international presence, the moat of J. B. Chemicals is less pronounced. These larger companies benefit from a stronger global brand presence, more extensive research and development resources, and a broader product range, giving them a significant competitive advantage.

In summary, J. B. Chemicals & Pharmaceuticals Limited is well positioned in its core segments, but has a less pronounced moat compared to industry leaders. Competitiveness could be enhanced through strategic expansions and innovations in new product categories.

Revenue Growth: 10% (estimated for 2026)
Profit Growth: 8% (estimated for 2026)
R&D Expenses: 7% of revenue (2025)

J. B. Chemicals & Pharmaceuticals Limited has shown solid revenue growth of around 10% in recent years, attributed to a strong product pipeline and successful market expansions. The company consistently invests in research and development, accounting for about 7% of revenue, to strengthen its competitiveness and innovation capabilities.

Profit margins have also improved positively, with an estimated profit growth of 8% in 2026. This indicates that the company operates efficiently and manages its cost structure well.

Overall, J. B. Chemicals & Pharmaceuticals Limited demonstrates stable financial performance and a strategic focus on growth and innovation. These factors could make the stock an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 1.8% (estimated for 2026)

J. B. Chemicals & Pharmaceuticals Limited has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 1.8%, which can be considered moderate compared to other companies in the industry.

The company has a solid financial position and demonstrates a reliable dividend policy. Dividends have been consistently paid in recent years, indicating a stable earnings situation and a responsible financial strategy. Analysts expect the company to maintain its dividend policy unless significant negative market changes occur.